Novartis AG (NYSE:NVS) has tumbled 1.3% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 2.8% in the last four weeks. The stocks have underperformed the S&P 500 by 0.12% during the past week but Novartis AG (NYSE:NVS) it has outperformed the index in 4 weeks by 1.86%.
Novartis AG (NYSE:NVS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $78.16 and $77.52 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $78.28. The buying momentum continued till the end and the stock did not give up its gains. It closed at $77.91, notching a gain of 1.33% for the day. The total traded volume was 3,353,040 . The stock had closed at $76.89 on the previous day.
The company shares have dropped -23.71% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $106.84 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $77.40 and the 200 Day Moving Average price is recorded at $77.77.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Morgan Stanley downgrades the rating on Novartis AG (NYSE:NVS). The brokerage firm has issued a Underperform rating on the shares. The shares were previously rated Equal-weight. The rating by the firm was issued on April 12, 2016. Currently the company Insiders own 0.01% of Novartis AG shares according to the proxy statements. Institutional Investors own 9.96% of Novartis AG shares.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.